Quantcast
Last updated on April 21, 2014 at 7:45 EDT

Latest TNF inhibitor Stories

2011-08-19 09:02:00

CAMBRIDGE, Mass., Aug. 19, 2011 /PRNewswire/ -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA((TM))) technology, today announced results of a pilot study to measure biomarkers of inflammation from patients with Crohn's disease. The precise measurement of low abundance cytokines, which was possible using Quanterix's high sensitivity digital ELISA, allowed significant changes to be detected...

2011-08-10 05:11:00

MUMBAI, August 10, 2011 /PRNewswire/ -- - Revamilast is a PDE4 inhibitor, under development for Asthma, Rheumatoid Arthritis and other inflammatory disorders - The molecule successfully completed pre-clinical trials and Phase I studies - Phase I studies on healthy volunteers were carried out mainly in the UK - Glenmark has initiated global Phase IIb studies for both indications in Europe and...

2011-07-25 02:00:00

MELBOURNE, Australia, July 25, 2011 /PRNewswire/ -- A new policy recommendation released on 20 July by the World Health Organization (WHO) warns against the use of serological (blood) tests to diagnose active tuberculosis (TB). Serological tests measure antibodies to TB in serum and are different to QuantiFERON, which measures responses of white blood cells to TB specific proteins. Active tuberculosis occurs when the TB organism has overcome the body's immune defences and proliferates...

2011-07-21 16:11:00

HORSHAM, Pa., July 21, 2011 /PRNewswire/ -- Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy. REMICADE® was...

2011-07-01 08:35:02

Tokyo, July 1, 2011 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they have received approval from Japan's Ministry of Health, Labour, and Welfare (MHLW) for polyarticular juvenile idiopathic arthritis (JIA) as an additional indication of Humira(R) (adalimumab) Pre-filled Syringe 40 mg/0.8 mL for Subcutaneous Injection, a fully human anti-TNF-α monoclonal antibody jointly developed by the two companies in Japan.In addition to the new indication,...

2011-06-21 21:49:13

2 disease-modifying antirheumatic drugs, TNF inhibitors and hydroxychloroquine, are associated with a reduced risk for the development of diabetes in psoriasis and rheumatoid arthritis patients Individuals with systemic inflammatory conditions, such as rheumatoid arthritis (RA) and psoriasis, experience a 1.5 to 2-fold increased rate of cardiovascular disease. Previous research suggests that inflammation and insulin resistance, linked with these conditions, likely accelerate the development...

2011-06-21 21:43:57

In a study that included nearly 14,000 patients with rheumatoid arthritis or psoriasis, the use of certain disease-modifying antirheumatic drugs was found to lower the risk of diabetes, according to a study in the June 22/29 issue of JAMA. Two common systemic inflammatory conditions, rheumatoid arthritis (RA) and psoriasis, predispose patients to insulin resistance and may place patients at risk for diabetes mellitus (DM). The treatment of psoriasis and RA includes disease-modifying...

2011-05-27 13:08:38

Separate study shows that the risk of mortality is the same with both Only three percent (n=181) of patients in the study cohort receiving anti-tumour necrosis factor agents (anti-TNFs) for treatment of their arthritis developed a first cancer within nine years and overall risk was not dependent on the type of arthritis. The nine year follow-up study conducted at Gentofte University Hospital, Denmark demonstrated that relative risk ((RR)=1.03 (95%confidence interval 0.82-1.30)) was not...

2011-05-27 09:00:00

LONDON and BRUSSELS, May 27, 2011 /PRNewswire/ -- UCB today announced data which showed that the addition of Cimzia® (certolizumab pegol) to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis (RA) patients. Consistent efficacy was observed across patients taking certolizumab pegol whether they had previously received TNF inhibitors or not and whether they received certolizumab pegol monotherapy* or with...

2011-05-25 15:14:53

Study findings suggest that it may be possible to identify candidates Data presented today at the EULAR 2011 Annual Congress demonstrated that initial treatment with adalimumab (Humira, ADA) plus methotrexate in early RA patients can provide high levels of disease control in many patients, and may also offer the opportunity to change future treatment options for some. Results of a study of 1032 patients with early (less than one year), active RA initially assessed response to treatment after...